4 active not recruiting, 2 completed, 1 enrolling by invitation, 1 recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Aura Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma Observational - Choroidal Melanoma, Indeterminate Lesions | Enrolling by invitation | Aura Biosciences | 100 | 2026-03-27 | 2026-08-19 | |
| Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects Non-interventional, digital, patient-reported, study - Choroidal Melanoma, Indeterminate Lesions | Active not recruiting | Aura Biosciences | 15 | 2025-11-12 | 2026-10-22 | |
| Suprachoroidal Administration in Subjects With Metastases to the Choroid AU-011, SCS Microinjector, Laser - Eye Cancer, Primary Cancer | Phase 2 | Recruiting | Aura Biosciences | 24 | 2024-12-16 | 2026-10-08 |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Bel-sar, Suprachoroidal Microinjector, Infrared Laser - Choroidal Melanoma, Indeterminate Lesions | Phase 3 | Active not recruiting | Aura Biosciences | 108 | 2023-12-06 | 2026-10-13 |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration - Non-muscle-invasive Bladder Cancer, NMIBC | Phase 1 | Active not recruiting | Aura Biosciences | 55 | 2022-09-26 | 2026-08-06 |
| Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) Standard of Care, AU-011 - Choroidal Melanoma, Indeterminate Lesions | Terminated | Aura Biosciences | 2 | 2022-04-14 | 2023-08-09 | |
| Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma AU-011, Suprachoroidal Microinjector, PDT Laser - Uveal Melanoma, Ocular Melanoma | Phase 2 | Completed | Aura Biosciences | 22 | 2020-08-05 | 2025-03-03 |
| A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma Choroidal Melanoma, Indeterminate Lesions of Eye | Active not recruiting | Aura Biosciences | 63 | 2019-03-27 | 2026-05-22 | |
| Study in Subjects With Small Primary Choroidal Melanoma Light-activated AU-011, Laser Activation - Uveal Melanoma, Ocular Melanoma | Phase 1 / Phase 2 | Completed | Aura Biosciences | 57 | 2017-02-27 | 2024-02-01 |
Uveal Melanoma (7) · Eye Neoplasms (5) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Neoplasms (1)
Lasers (1) · Standard of Care (1) · Watchful Waiting (1)
United States (8) · Australia (3) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · New Zealand (1) · Spain (1) · United Kingdom (1)